"Nano- Biotechnological Advances For Diabetic Wound Healing 10Other trends in the wound healing improve the prevention or the actual healing bymass education through standardized education and even training programs that are aimed atencouraging the establishment of well-functioning wound treatment concepts. However,despite all the trends, the possibility of any future development on all this is primarilyimpaired by the challenges that still haven‘t been gotten rid entirely. They include the lackregistration of patient data in some hospitals or even countries. Without these data, researchat times is rendered inevitable. Patients also have limited knowledge on their health regardingdiabetes and the wounds which impair the development of clinical treatments through latediagnosis. The other challenge is also attributed to sufficient research on the wounds healingprocess that is mainly attributed to the lack of funding to the researchers. There is also a lackof an accepted wound classification that deters the future research on the healing process ofthe wounds especially in people with diabetes.Gene therapy for diabetic wound healing Nano- Biotechnological Advances For Diabetic Wound Healing 11ConclusionAs seen there is a rapid advancement in the wound care since the past decade; thatcomes as a result of our increasing understanding of biology. The advancement is in a betterposition to continue because of the ever-changing technology and the extensive research thatare still ongoing.However, we should not always focus on utilizing the new technology andforgetting about wound care. The selection for the dressing, however, depends very much onthe skills of the practitioner conducting the assessment of the given injury and theirknowledge on how to provide an optimum environment for the wound to heal by use of newinteractive dressings.Reference List Ajazuddin, S.2010.Applications of Novel Drug Delivery System for HerbalFormulations. Fitoterapia, pp.680– 689.Andreopoulos, F. and Persaud, I. (2006). Delivery of Basic Fibroblast Growth Factor (Bfgf)From Photoresponsive Hydrogel Scaffolds. Biomaterials, 27(11), pp.2468-2476.Ansari, K. A., Vavia, P. R., Trotta, F., Cavalli, R. (2011). Cyclodextrin-Based Nanospongesfor Delivery Of Resveratrol: In Vitro Characterization, Stability, Cytotoxicity, AndPermeation Study. AAPS PharmSciTech, 4(12), pp.279– 286Cai, W. (2007). Multimodality Imaging Of Vascular Endothelial Growth Factor and VascularEndothelial Growth Factor Receptor Expression. Frontiers in Bioscience, 12(8-12),pp.42-67.Cao, L., Arany P. R., Wang Y. S., & Mooney D. J. (2009). Promoting Angiogenesis viaManipulation of VEGF Responsiveness with Notch Signaling. Biomaterials. pp.4085– 4093 (doi:10.1016/j.biomaterials.2009.04.051)10.1016/j.biomaterials.2009.04.Nano- Biotechnological Advances For Diabetic Wound Healing 12Choi, J.S., Leong, K.W. & Yoo, H.S. (2008) =In Vivo Wound Healing Of Diabetic UlcersUsing Electrospun Nanofibers Immobilized With Human Epidermal Growth Factor(EGF)‘, Biomaterials, 29(5), pp. 587–596. doi: 10.1016/j.biomaterials.2007.10.012.Ciolino, H. and Yeh, G. (1999). The Flavonoid Galangin Is An Inhibitor Of CYP1A1Activity And An Agonist/Antagonist Of The Aryl Hydrocarbon Receptor. BritishJournal of Cancer, 79(9/10), pp.1340-1346.Cross, M., Dexter, T. M. (1991). Growth Factors In Development, Transformation, AndTumorigenesis. Cell 64, pp.271–280 (doi: 10.1016/0092-8674(91)90638-F)Daly, J. (2011). Wound Macrophages as Key Regulators of Repair: Origin, Phenotype, andFunction. Yearbook of Surgery, 2011, pp.210-211.Endean, P. (2005). Wound healing. Nursing Standard, 20(10), pp.67-68.Yudovsky, D.,Nouvong, A. and Pilon, L. (2010). Hyperspectral Imaging in Diabetic Foot WoundCare. Journal of Diabetes Science and Technology, 4(5), pp.1099-1113.Falcao, M. (2012). Diabetic Retinopathy: Understanding Pathologic Angiogenesis andExploring its Treatment Options. The Open Circulation & Vascular Journal, 3(1),pp.30-42.Ghazi, K., Deng-Pichon, U., Warnet, J. and Rat, P. (2012). Hyaluronan Fragments ImproveWound Healing on In Vitro Cutaneous Model through P2X7 Purinoreceptor BasalActivation: Role of Molecular Weight. PLoS ONE, 7(11), pp.48351.Goldman, R. (2004).Growth Factors and Chronic Wound Healing: Past, present and future.Advanced Skin Wound Care, 17(1), pp.24–35 Nano- Biotechnological Advances For Diabetic Wound Healing 13GRIFFITH, L. (2002). Emerging Design Principles in Biomaterials and Scaffolds for TissueEngineering. Annals of the New York Academy of Sciences, 961(1), pp.83-95.Hanft, J.R., Pollak, R.A., Barbul, A., Van, G., Kwon, P.S., Gray, S.M. (2008). Phase I Trialon the Safety of Topical Rhvegf on Chronic Neuropathic Diabetic. Foot ulcersJWound Care, 17, pp.30–32, 34–37Komori, M., Tomizawa, Y., Takada, K. and Ozaki, M. (2005). A Single Local Application ofRecombinant Human Basic Fibroblast Growth Factor Accelerates InitialAngiogenesis During Wound Healing in Rabbit Ear Chamber. Anesthesia &Analgesia, 100(3), pp.830-834.Zhang, L., Liu, Q., Lu, L., Zhao, X., Gao, X.,&Wang, Y. (2011). Astragaloside IV StimulatesAngiogenesis And Increases Hypoxia-Inducible Factor-1a Accumulation ViaPhosphatidylinositol 3-Kinase/Akt Pathway.J. Pharmacol. Exp. Ther, 338 pp. 485– 491Li, J., Chen, J. and Kirsner, R. (2007). Pathophysiology of Acute Wound Healing. Clinics inDermatology, 25(1), pp.9-18.Maruyama, K., Asai, J., Ii, M., Thorne, T., Losordo, D. and D'Amore, P. (2007). DecreasedMacrophage Number and Activation Lead to Reduced Lymphatic Vessel Formationand Contribute to Impaired Diabetic Wound Healing. The American Journal ofPathology, 170(4), pp.1178-1191.Qi, Q., Mao, Y., Yi, J., Li, D., Zhu, K. and Cha, X. (2014). Anti-Fibrotic Effects ofAstragaloside IV in Systemic Sclerosis. Cellular Physiology and Biochemistry, 34(6),pp.2105-2116. Nano- Biotechnological Advances For Diabetic Wound Healing 14Qi, W., Yang, C., Dai, Z., Che, D., Feng, J., Mao, Y., Cheng, R., Wang, Z., He, X., Zhou, T.,Gu, X., Yan, L., Yang, X., Ma, J. and Gao, G. (2014). High Levels of PigmentEpithelium–Derived Factor in Diabetes Impair Wound Healing Through Suppressionof Wnt Signaling. Diabetes, 64(4), pp.1407-1419.Blakytny, R., & Jude, E. (2006). The molecular biology of chronic wounds and delayedhealing in diabetes Diabet Med, 23. pp.594–608Wood, S., Jayaraman, V., Huelsmann, E.J., Bonish, B., Burgad, D., & Sivaramakrishnan, G.(2014).Pro-Inflammatory Chemokine CCL2 (MCP-1) Promotes Healing In DiabeticWounds By Restoring The Macrophage Response.PLoS One, 9, pp.91574Saboo, A., Rathnayake, A., Vangaveti, V. and Malabu, U. (2016). Wound healing effects ofdipeptidyl peptidase-4 inhibitors: An emerging concept in management of diabeticfoot ulcer—A review. Diabetes & Metabolic Syndrome: Clinical Research &Reviews, 10(2), pp.113-119.Lucas, T., Waisman, A., Ranjan, R., Roes, J., Krieg, T., &Müller, W. (2010). DifferentialRoles Of Macrophages In Diverse Phases Of Skin Repair. J. Immunol, 184, pp. 3964– 77Thangarajah, H., Yao, D., Chang, E., Shi, Y., Jazayeri, L., Vial, I., Galiano, R., Du, X.,Grogan, R., Galvez, M., Januszyk, M., Brownlee, M. and Gurtner, G. (2009). Themolecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.Proceedings of the National Academy of Sciences, 106(32), pp.13505-13510.Xing, J.; Chen, X.; Zhong, D. (2005) Absorption and enterohepatic circulation of baicalin inrats Life Sci., 78. 140– 146 "